

Philip Savage

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4690144/publications.pdf>

Version: 2024-02-01

60
papers

557
citations

759233

12
h-index

642732

23
g-index

61
all docs

61
docs citations

61
times ranked

775
citing authors

#	ARTICLE	IF	CITATIONS
1	Cancer Therapy Approval Timings, Review Speed, and Publication of Pivotal Registration Trials in the US and Europe, 2010-2019. <i>JAMA Network Open</i> , 2022, 5, e2216183.	5.9	27
2	Development and economic trends in anticancer drugs licensed in the UK from 2015 to 2019. <i>Drug Discovery Today</i> , 2021, 26, 301-307.	6.4	8
3	Increasing the human chorionic gonadotrophin cut-off to ≥ 1000 IU/l for starting actinomycin D in post-molar gestational trophoblastic neoplasia developing resistance to methotrexate spares more women multi-agent chemotherapy. <i>ESMO Open</i> , 2021, 6, 100110.	4.5	9
4	The impact of new cancer drug therapies on site specialised cancer treatment activity in a UK cancer network 2014-2018. <i>Journal of Oncology Pharmacy Practice</i> , 2020, 26, 93-98.	0.9	5
5	Chemotherapy Curability in Leukemia, Lymphoma, Germ Cell Tumors and Gestational Malignancies: A Reflection of the Unique Physiology of Their Cells of Origin. <i>Frontiers in Genetics</i> , 2020, 11, 426.	2.3	3
6	Demographics, natural history and treatment outcomes of non-molar gestational choriocarcinoma: a UK population study. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2020, 127, 1102-1107.	2.3	17
7	A case of intraplacental gestational choriocarcinoma; characterised by the methylation pattern of the early placenta and an absence of driver mutations. <i>BMC Cancer</i> , 2019, 19, 744.	2.6	17
8	Advances in current and emerging therapeutics for gestational trophoblast malignancies. <i>Expert Opinion on Orphan Drugs</i> , 2019, 7, 27-36.	0.8	0
9	Power Doppler Quantification in Assessing Gestational Trophoblastic Neoplasia. <i>Ultraschall in Der Medizin</i> , 2018, 39, 206-212.	1.5	3
10	Approvals in 2016: cost-benefit challenges of new anticancer agents. <i>Nature Reviews Clinical Oncology</i> , 2017, 14, 133-134.	27.6	5
11	Cancer Referral and Treatment Activity 2010-2015: A Population-Based Study from Vancouver Island. <i>Current Oncology</i> , 2016, 23, 626-629.	2.2	4
12	Hormonal contraceptive use before β hCG remission does not increase the risk of gestational trophoblastic neoplasia following complete hydatidiform mole: a historical database review. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2016, 123, 1330-1335.	2.3	21
13	Chemotherapy curable malignancies and cancer stem cells: a biological review and hypothesis. <i>BMC Cancer</i> , 2016, 16, 906.	2.6	17
14	Clinical characteristics and outcomes for patients with an initial emergency presentation of malignancy: A 15 month audit of patient level data. <i>Cancer Epidemiology</i> , 2015, 39, 86-90.	1.9	9
15	Development and economic trends in cancer therapeutic drugs: a 5-year update 2010-2014. <i>British Journal of Cancer</i> , 2015, 112, 1037-1041.	6.4	50
16	Effects of Single-Agent and Combination Chemotherapy for Gestational Trophoblastic Tumors on Risks of Second Malignancy and Early Menopause. <i>Journal of Clinical Oncology</i> , 2015, 33, 472-478.	1.6	67
17	Brain metastases in gestational trophoblast neoplasia: An update on incidence, management and outcome. <i>Gynecologic Oncology</i> , 2015, 137, 73-76.	1.4	61
18	Clinical observations on chemotherapy curable malignancies: unique genetic events, frozen development and enduring apoptotic potential. <i>BMC Cancer</i> , 2015, 15, 11.	2.6	9

#	ARTICLE	IF	CITATIONS
19	Malignant spinal cord compression: NICE guidance, improvements and challenges. QJM - Monthly Journal of the Association of Physicians, 2014, 107, 277-282.	0.5	44
20	Partial molar pregnancy after intracytoplasmic sperm injection occurring as a result of diploid sperm usage. Journal of Assisted Reproduction and Genetics, 2013, 30, 761-764.	2.5	9
21	Development and economic trends in cancer therapeutic drugs: An updated analysis of modern and historical treatment costs compared to the contemporary GDP per capita.. Journal of Clinical Oncology, 2013, 31, 259-259.	1.6	2
22	Development and economic trends in cancer therapeutic drugs in the UK from 1955 to 2009. Journal of Oncology Pharmacy Practice, 2012, 18, 52-56.	0.9	16
23	Signet Ring Cell Carcinoma of the Bladder and Urachus. British Journal of Medical and Surgical Urology, 2011, 4, 2-7.	0.2	0
24	The Treatment of Bisphosphonate Refractory Hypercalcaemia in Renal Cell Carcinoma with Sunitinib. British Journal of Medical and Surgical Urology, 2010, 3, 172-174.	0.2	0
25	Small Bowel Perforation in a Patient with Metastatic Renal Cancer Treated with Radiotherapy and Sunitinib. British Journal of Medical and Surgical Urology, 2010, 3, 253-255.	0.2	0
26	Why does cytotoxic chemotherapy cure only some cancers?. Nature Clinical Practice Oncology, 2009, 6, 43-52.	4.3	100
27	Multidisciplinary care. , 2008, , 267-278.		1
28	Practical issues in the management of low-risk gestational trophoblast tumors. Journal of reproductive medicine, The, 2008, 53, 774-80.	0.2	12
29	Expansion of CD8+ Cytotoxic T Cells in vitro and in vivo Using MHC Class I Tetramers. Tumor Biology, 2007, 28, 70-76.	1.8	23
30	Immunotherapy with Antibody-Targeted HLA Class I Complexes: Results of in vivo Tumour Cell Killing and Therapeutic Vaccination. Tumor Biology, 2007, 28, 205-211.	1.8	5
31	Artificial antigen-presenting cells: a natural approach to chronic viral infection?. Future HIV Therapy, 2007, 1, 345-346.	0.4	0
32	Malignant melanoma (non-metastatic). Clinical Evidence, 2007, 2007, .	0.2	1
33	The outcome of patients with relapsed gestational trophoblastic neoplasm (GTN) after the completion of chemotherapy. Journal of Clinical Oncology, 2006, 24, 5033-5033.	1.6	2
34	A new approach to immunotherapy: for AIDS and AIDS-related malignancies. Journal of HIV Therapy, 2006, 11, 64-6.	0.6	0
35	Immortalized HLA Class I Negative Daudi B Cells Coated with HLA/Peptide Monomers Promote Efficient In Vitro Expansion of Antigen Specific CD8+ T Cells.. Blood, 2005, 106, 3908-3908.	1.4	0
36	Epidemiology of cancer in women during reproductive life. , 0, , 3-12.		1

#	ARTICLE	IF	CITATIONS
37	Radiotherapy and cancer. , 0, , 55-60.		0
38	Assisted reproductive technology for preserving fertility in women with cancer. , 0, , 63-72.		0
39	Fertility after cancer therapy. , 0, , 73-86.		0
40	Fertility-preserving surgery in women with cancer of the cervix. , 0, , 87-100.		1
41	Gonadal function and fertility issues in children and young people treated for cancer. , 0, , 101-108.		0
42	Management of cervical intraepithelial neoplasia during pregnancy. , 0, , 111-114.		0
43	Impact of LLETZ on subsequent pregnancies. , 0, , 115-124.		0
44	Ovarian masses and malignancies. , 0, , 125-132.		0
45	Cervical and endometrial cancer in relation to pregnancy. , 0, , 133-144.		1
46	Imaging techniques. , 0, , 147-154.		0
47	Serum markers for gynaecological cancer in the reproductive years. , 0, , 155-178.		0
48	Diagnostic dilemmas in cellular pathology. , 0, , 179-184.		0
49	Placental and fetal malignancies. , 0, , 187-204.		2
50	Gestational trophoblastic neoplasia. , 0, , 205-226.		0
51	Pregnancy and breast cancer. , 0, , 229-242.		0
52	Melanoma and reproductive health. , 0, , 257-264.		0
53	Consensus views arising from the 55th Study Group: Cancer and Reproductive Health. , 0, , 281-284.		1
54	Practical issues in cytotoxic chemotherapy usage. , 0, , 1-12.		0

#	ARTICLE	IF	CITATIONS
55	Gestational trophoblast tumours. , 0 , 304-312.		0
56	Chemotherapy in the treatment of pregnant women with cancer. , 0 , 23-54.		0
57	Cancer genetics and reproduction. , 0 , 13-22.		0
58	The haematological malignancies. , 0 , 243-256.		2
59	Gestational Trophoblast Tumours. , 0 , 66-75.		2
60	Management of gestational trophoblast tumours. , 0 , 403-412.		0